Arthur L. Caplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arthur L. Caplan has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
David Magnus
2 shared publicationsGlenn McGee
Center for Bioethics University of Pennsylvania Philadelphia, PA 19104
2 shared publicationsAlexander M. Capron
1 shared publicationAllison Kennedy
1 shared publicationAngus Dawson
1 shared publicationAnne Mandich
1 shared publication
Latest Publications
- 20 June 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (25) , e36
The OHRP and SUPPORT
We are a group of scholars and leaders in bioethics and pediatrics with extensive experience in ethical and regulatory issues in pediatrics and human subjects research. We urge the Office for Human Research Protections (OHRP) to withdraw its notification to the institutions involved in the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT) that they failed to meet regulatory informed-consent requirements, in particular regarding reasonably foreseeable risks of enrollment in the study. We believe that this conclusion was a substantive error and will have adverse implications for future research.
- 20 June 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (25) , e36
The OHRP and SUPPORT
We are a group of scholars and leaders in bioethics and pediatrics with extensive experience in ethical and regulatory issues in pediatrics and human subjects research. We urge the Office for Human Research Protections (OHRP) to withdraw its notification to the institutions involved in the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT) that they failed to meet regulatory informed-consent requirements, in particular regarding reasonably foreseeable risks of enrollment in the study. We believe that this conclusion was a substantive error and will have adverse implications for future research.
- 26 September 2011
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 11 (10) , 1-5
The Use of Prisoners as Sources of Organs–An Ethically Dubious Practice
The movement to try to close the ever-widening gap between demand and supply of organs has recently arrived at the prison gate. While there is enthusiasm for using executed prisoners as sources of organs, there are both practical barriers and moral concerns that make it unlikely that proposals to use prisoners will or should gain traction. Prisoners are generally not healthy enough to be a safe source of organs, execution makes the procurement of viable organs difficult, and organ donation post-execution ties the medical profession too closely to the act of execution.
- 26 September 2011
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 11 (10) , 1-5
The Use of Prisoners as Sources of Organs–An Ethically Dubious Practice
The movement to try to close the ever-widening gap between demand and supply of organs has recently arrived at the prison gate. While there is enthusiasm for using executed prisoners as sources of organs, there are both practical barriers and moral concerns that make it unlikely that proposals to use prisoners will or should gain traction. Prisoners are generally not healthy enough to be a safe source of organs, execution makes the procurement of viable organs difficult, and organ donation post-execution ties the medical profession too closely to the act of execution.
- 1 July 2011
- Published by Elsevier in The Lancet
- Vol. 378 (9788) , 310-311
Time to mandate influenza vaccination in health-care workers
- 1 July 2011
- Published by Elsevier in The Lancet
- Vol. 378 (9788) , 310-311
Time to mandate influenza vaccination in health-care workers
- 1 June 2011
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 30 (6) , 1205-1208
Vaccination: Facts Alone Do Not Policy MakeDeadly Choices: How The Anti-Vaccine Movement Threatens Us All by Offit Paul A. New York (NY) : Basic Books , 2011 288 pp., $27.50The Panic Virus: A True Story Of Medicine, Science, And Fear by Mnookin Seth New York (NY) : Simon and Schuster , 2011 488 pp.; $26.99
- 1 June 2011
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 30 (6) , 1205-1208
Vaccination: Facts Alone Do Not Policy MakeDeadly Choices: How The Anti-Vaccine Movement Threatens Us All by Offit Paul A. New York (NY) : Basic Books , 2011 288 pp., $27.50The Panic Virus: A True Story Of Medicine, Science, And Fear by Mnookin Seth New York (NY) : Simon and Schuster , 2011 488 pp.; $26.99
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9766) , 621-622
The Havasu ‘Baaja tribe and informed consent
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9766) , 621-622
The Havasu ‘Baaja tribe and informed consent
- 1 November 2010
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 88 (5) , 583-584
Clinical Trials of Drugs and Vaccines Among the Desperately Poor in Poor Nations: Ethical Challenges and Ethical Solutions
Clinical research has been expanding into poor nations in recent years. In doing research in such settings, the response to challenges arising due to the vulnerability and resultant potential exploitation of very poor subject populations is heightened awareness of the need for adequate local oversight and regulation. More regulation, however, often is difficult to implement and may not be practical. The provision of benefit at the conclusion of clinical trials in poor nations or for poor people is a better response to the moral challenge of exploitation.
- 1 November 2010
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 88 (5) , 583-584
Clinical Trials of Drugs and Vaccines Among the Desperately Poor in Poor Nations: Ethical Challenges and Ethical Solutions
Clinical research has been expanding into poor nations in recent years. In doing research in such settings, the response to challenges arising due to the vulnerability and resultant potential exploitation of very poor subject populations is heightened awareness of the need for adequate local oversight and regulation. More regulation, however, often is difficult to implement and may not be practical. The provision of benefit at the conclusion of clinical trials in poor nations or for poor people is a better response to the moral challenge of exploitation.
- Open Access
- 1 November 2010
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 33 (11) , 1426-1427
Duty to Warn?—The Ethics of Disclosing Information about Possible Risks Associated with H1N1 Vaccination
IN THIS ISSUE OF SLEEP A LETTER TO THE EDITOR APPEARS FROM DAUVILLIERS AND COLLEAGUES1 REPORTING A POSSIBLE ASSOCIATION BETWEEN narcolepsy-cataplexy and H1N1 exposure believed to be primarily through the vaccine Pandemrix2 (GlaxoSmithKline), which contained the adjuvant ASO39. This report follows an earlier observation of an association by Swedish authorities, which led to the suspension of the use of this vaccine in Sweden and Finland.3
- 1 November 2010
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 33 (11) , 1426-1427
Open AccessDuty to Warn?—The Ethics of Disclosing Information about Possible Risks Associated with H1N1 Vaccination
IN THIS ISSUE OF SLEEP A LETTER TO THE EDITOR APPEARS FROM DAUVILLIERS AND COLLEAGUES1 REPORTING A POSSIBLE ASSOCIATION BETWEEN narcolepsy-cataplexy and H1N1 exposure believed to be primarily through the vaccine Pandemrix2 (GlaxoSmithKline), which contained the adjuvant ASO39. This report follows an earlier observation of an association by Swedish authorities, which led to the suspension of the use of this vaccine in Sweden and Finland.3
- 1 February 2010
- Published by Elsevier in The Lancet
- Vol. 375 (9713) , 444-445
Unlicensed pandemic influenza A H1N1 vaccines
- 1 February 2010
- Published by Elsevier in The Lancet
- Vol. 375 (9713) , 444-445
Unlicensed pandemic influenza A H1N1 vaccines
- 2 December 2009
- Published by Springer Nature in Nature Reviews Neuroscience
- Vol. 11 (1) , 61-69
Neurotalk: improving the communication of neuroscience research
Neuroscientists face increasing pressure to disseminate results and discuss their implications with the public. Illes and colleagues consider the challenges that they face and make specific recommendations for individuals and institutions to promote this process. There is increasing pressure for neuroscientists to communicate their research and the societal implications of their findings to the public. Communicating science is challenging, and the transformation of communication by digital and interactive media increases the complexity of the challenge. To facilitate dialogue with the public in this new media landscape, we suggest three courses of action for the neuroscience community: a cultural shift that explicitly recognizes and rewards public outreach, the identification and development of neuroscience communication experts, and ongoing empirical research on the public communication of neuroscience.
- 2 December 2009
- Published by Springer Nature in Nature Reviews Neuroscience
- Vol. 11 (1) , 61-69
Neurotalk: improving the communication of neuroscience research
Neuroscientists face increasing pressure to disseminate results and discuss their implications with the public. Illes and colleagues consider the challenges that they face and make specific recommendations for individuals and institutions to promote this process. There is increasing pressure for neuroscientists to communicate their research and the societal implications of their findings to the public. Communicating science is challenging, and the transformation of communication by digital and interactive media increases the complexity of the challenge. To facilitate dialogue with the public in this new media landscape, we suggest three courses of action for the neuroscience community: a cultural shift that explicitly recognizes and rewards public outreach, the identification and development of neuroscience communication experts, and ongoing empirical research on the public communication of neuroscience.